Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,201–1,300 of 15,747
Flisiak, R., Horban, A., Jaroszewicz, J., Kozielewicz, D., Mastalerz–Migas, A., Owczuk, R., Parczewski, M., Pawłowska, M., Piekarska, A., Simon, K. A., et al. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15979 · Cited by 97
Pardi, N., Carreño, J. M., O’Dell, G., Tan, J., Bajusz, C., Muramatsu, H., Rijnink, W. F., Strohmeier, S., Loganathan, M., Bielak, D. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32149-8 · Cited by 91
Fabiani, M., Ramigni, M., Gobbetto, V., Mateo‐Urdiales, A., Pezzotti, P., & Piovesan, C. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.17.2100420 · Cited by 101
Maleki, A., Look-Why, S., Manhapra, A., & Foster, C. S. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i3.9443 · Cited by 97
Klimek, L., Jutel, M., Akdiş, C. A., Bousquet, J., Akdiş, M., Torres, M. J., Agache, I. O., Canonica, G. W., Giacco, S. D., O’Mahony, L., et al. (2020) · Allergy · doi:10.1111/all.14726 · Cited by 85
‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
Parry, P. I., Lefringhausen, A., Turni, C., Neil, C., Cosford, R., Hudson, N. J., & Gillespie, J. (2023) · Biomedicines · doi:10.3390/biomedicines11082287 · Cited by 122
“Pfizer admitted that its phase 3 clinical trial [12] did not test for viral transmission [13].”
BackgroundNano toolbox in immune modulation and nanovaccines
Azharuddin, M., Zhu, G. H., Sengupta, A., Hinkula, J., Slater, N. K. H., & Patra, H. K. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.03.011 · Cited by 93
Same yet different — how lymph node heterogeneity affects immune responses
de Casas, P. C., Knöpper, K., Sarkar, R. D., & Kastenmüller, W. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00965-8 · Cited by 108
“In the prominent case of COVID-19, the available vaccines succeeded in inducing a protective, systemic immune response 235 but failed in generating local immunity via lung-resident memory cells in contrast to the infection with the virus 236–239 .”
Golan, Y., Prahl, M. K., Cassidy, A. G., Gay, C., Wu, A. H. B., Jigmeddagva, U., Lin, C. Y., Gonzalez, V. J., Basilio, E., Chidboy, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.777103 · Cited by 96
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
Liebers, N., Speer, C., Benning, L., Bruch, P., Kraemer, I., Meißner, J., Schnitzler, P., Kräusslich, H., Dreger, P., Müller‐Tidow, C., et al. (2021) · Blood · doi:10.1182/blood.2021013445 · Cited by 94
Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis
Ling, Y., Zhong, J., & Luo, J. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27203 · Cited by 89
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 116
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 108
Distinctive features of severe SARS-CoV-2 pneumonia
Budinger, G. R. S., Misharin, A. V., Ridge, K. M., Singer, B. D., & Wunderink, R. G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149412 · Cited by 90
Ammirati, E., Cavalotti, C., Milazzo, A., Pedrotti, P., Soriano, F., Schroeder, J. W., Morici, N., Giannattasio, C., Frigerio, M., Metra, M., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100774 · Cited by 86
RetractedCoyle, P. V., Chemaitelly, H., Ben Hadj Kacem, M. A., Abdulla Al Molawi, N. H., El Kahlout, R. A., Gilliani, I., Younes, N., Al Anssari, G. A. A. A., Al Kanaani, Z., Al Khal, A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102646 · Cited by 86
Human coronaviruses: Origin, host and receptor
Tang, G., Liu, Z., & Chen, D. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105246 · Cited by 108
Recent progress in mRNA cancer vaccines
Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 103
“21 The COVID-19 pandemic has accentuated the immense potential of mRNA technology, 6,7,9 offering valuable insights for the development of mRNA-based cancer vaccines.”
BackgroundmRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 110
“5:10) for Spikevax (the Moderna vaccine) [8,13].”
MethodCabezas, C., Coma, E., Mora, N., Li, X., Martínez, M., Avilés, F. F., Fàbregas, M., Hermosilla, E., Jover, A., Contel, J. C., et al. (2021) · BMJ · doi:10.1136/bmj.n1868 · Cited by 97
Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study
Omeish, H. A., Najadat, A. A. A., Al-Azzam, S. I., Tarabin, N., Hmaid, A. A., Al-Gallab, N., Abbas, H., Rababah, L. K., Rabadi, M., Karasneh, R. A., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1981086 · Cited by 95
“Pfizer-BioNTech is a nucleic acid-based mRNA vaccine with an efficacy of 95%.(14) Sinopharm is an inactivated vaccine with an efficacy of 79%.”
BackgroundResultGöbel, C. H., Heinze, A., Karstedt, S. C., Morscheck, M., Tashiro, L., Cirkel, A., Hamid, Q. A., Halwani, R., Temsah, M.-H. A., Ziemann, M., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab169 · Cited by 85
Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
Lai, F. T. T., Huang, L., Chui, C. S. L., Wan, E. Y. F., Li, X., Wong, C. K. H., Chan, E. W. W., Ma, T., Lum, D. H., Leung, J. C. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28068-3 · Cited by 88
Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents
White, E. M., Yang, X., Blackman, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104849 · Cited by 85
Friedl, J. D., Nele, V., Rosa, G. D., & Bernkop‐Schnürch, A. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202103347 · Cited by 95
Zisis, S. N., Durieux, J. C., Mouchati, C., Perez, J. A., & McComsey, G. A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac228 · Cited by 85
“Immunization is effective in preventing infection [13]”
Self-citationNewman, J., Thakur, N., Peacock, T. P., Bialy, D., Elrefaey, A. M. E., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01163-3 · Cited by 85
Arregocés-Castillo, L., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón-Medrano, L., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00035-6 · Cited by 97
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 99
“Short-term adverse effects, such as injection-site pain, systemic fever, and fatigue, are prevalent following mRNA COVID-19 vaccination via i.m. injection [262].”
Backgroundde Carvalho, B. G., Ceccato, B. T., Michelon, M., Han, S. W., & de la Torre, L. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010141 · Cited by 103
Escalona-Rayo, O., Zeng, Y., Knol, R. A., Kock, T. J. F., Aschmann, D., Slütter, B., & Kros, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115065 · Cited by 98
Jeon, M., Kim, J., Oh, C. E., & Lee, J. Y. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e114 · Cited by 97
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination
de Assis, R. R., Jain, A., Nakajima, R., Jasinskas, A., Khan, S., Palma, A. M., Parker, D. M., Chau, A. H., Specimen Collection Group, Hosseinian, S., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00396-3 · Cited by 88
A structural view of the SARS-CoV-2 virus and its assembly
Hardenbrook, N. J., & Zhang, P. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.011 · Cited by 108
“The two-proline mutation that was identified in previous MERS-CoV and SARSCoV work to stabilize S in its prefusion conformation [109] has been used in the development of both the Pfizer and Moderna mRNA vaccines, increasing the efficacy [7 ,14,15].”
Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review
Keshavarz, P., Yazdanpanah, F., Rafiee, F., & Mizandari, M. (2021) · Academic Radiology · doi:10.1016/j.acra.2021.04.007 · Cited by 83
Zelkoski, A. E., Lu, Z., Sukumar, G., Dalgard, C. L., Said, H., Alameh, M., Mitre, E. E. S., & Malloy, A. M. W. (2025) · npj Vaccines · doi:10.1038/s41541-025-01124-x · Cited by 132
Case of Guillain-Barré syndrome following COVID-19 vaccine
Hasan, T., Khan, M., Khan, F., & Hamza, G. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243629 · Cited by 99
Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2211055 · Cited by 78
Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., García-Sastre, A., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.02648-20 · Cited by 83
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Tang, P., Coyle, P., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 83
Winkeljann, B., Keul, D. C., & Merkel, O. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.008 · Cited by 95
mRNA lipid nanoparticle phase transition
Trollmann, M. F. W., & Böckmann, R. A. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.08.037 · Cited by 95
“Two LNP-based mRNA vaccines which showed a high efficacy against SARS-CoV-2 in their third clinical trial were Comirnaty (95% (14), BioNTech & Pfizer) and Elasomeran (94.”
BackgroundInfluentialFernández‐Nieto, D., Hammerle, J., Fernández-Escribano, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17250 · Cited by 84
The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis
Chew, N., Ow, Z. G. W., Teo, V. X. Y., Heng, R. R. Y., Ng, C. H., Lee, C., Low, A. F.-H., Chan, M. Y., Yeo, T., Tan, H. C., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.04.003 · Cited by 102
Dufour, J., Marjot, T., Becchetti, C., & Tilg, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326792 · Cited by 94
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · doi:10.1101/2022.02.24.22271440 · Cited by 84
Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
Ou, M. T., Boyarsky, B. J., Motter, J. D., Greenberg, R. S., Teles, A. T., Ruddy, J. A., Krach, M. R., Jain, V. S., Werbel, W. A., Avery, R. K., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003780 · Cited by 89
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 110
Bruxvoort, K. J., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Lee, G. S., Tian, Y., Florea, A., Takhar, H. S., Tubert, J. E., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100134 · Cited by 95
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Khandker, S. S., Godman, B., Jawad, M. I., Meghla, B. A., Tisha, T. A., Khondoker, M. U., Haq, M. A., Charan, J., Talukder, A. A., Azmuda, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9121387 · Cited by 94
“Unexpected events such as right axillary lymphadenopathy, right leg paresthesia, paroxysmal ventricular ar‐ rhythmia, and shoulder injury were reported among BNT162b2 recipients (Figure 5) [94].”
BackgroundSTING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2
Zhang, Y., Yan, J., Hou, X., Wang, C., Kang, D. D., Xue, Y., Du, S., Deng, B., McComb, D. W., Liu, S., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04883 · Cited by 88
Access to COVID-19 vaccines: Global approaches in a global crisis
OECD (2021) · OECD policy responses to coronavirus (Covid-19) · doi:10.1787/c6a18370-en · Cited by 119
González, S. E., Olszevicki, S., Salazar, M. R., Calabria, A., Regairaz, L., Marín, L., Campos, P., Varela, T., González, V., Ceriani, L., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101126 · Cited by 89
Barin, B., Kasap, U., Selçuk, F., Volkan, E., & Uluçkan, Ö. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00305-0 · Cited by 90
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 86
Jafarzadeh, A., Nemati, M., Jafarzadeh, S., Nozari, P., & Mortazavi, S. M. J. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01786-7 · Cited by 86
Ammitzbøll, C. G., Bartels, L. E., Andersen, J. B., Vils, S. R., Mistegaard, C. E., Johannsen, A. D., Hermansen, M. F., Thomsen, M. K., Erikstrup, C., Hauge, E., et al. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11299 · Cited by 83
The COVID-19 Vaccines: Recent Development, Challenges and Prospects
Yan, Y., Pang, Y. X., Lyu, Z., Wang, R., Wu, X., You, C., Zhao, H., Manickam, S., Lester, E. H., Wu, T., et al. (2021) · Vaccines · doi:10.3390/vaccines9040349 · Cited by 94
Mallory, K. L., Taylor, J. A., Zou, X., Waghela, I. N., Schneider, C. G., Sibilo, M. Q., Punde, N. M., Perazzo, L., Savransky, T., Sedegah, M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00345-0 · Cited by 96
Influenza Vaccines: Successes and Continuing Challenges
Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab269 · Cited by 95
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz‐Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., & Pałgan, K. (2021) · Cells · doi:10.3390/cells10081952 · Cited by 88
“After the first dose, the effectiveness of the preparation was estimated at approximately 52% [15].”
BackgroundSocioeconomic disparities and COVID-19 vaccination acceptance: a nationwide ecologic study
Caspi, G., Dayan, A., Eshal, Y., Liverant-Taub, S., Twig, G., Shalit, U., Lewis, Y. E., Shina, A., & Caspi, O. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.030 · Cited by 81
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses
Ibarrondo, F. J., Hofmann, C., Fulcher, J. A., Goodman‐Meza, D., Mu, W., Hausner, M. A., Ali, A., Balamurugan, A., Taus, E., Elliott, J. E., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c03972 · Cited by 83
Martínez‐Baz, I., Miqueleiz, A., Casado, I., Navascués, A., Trobajo‐Sanmartín, C., Burgui, C., Guevara, M., Ezpeleta, C., Castilla, J., & Working Group for the Study of COVID-19 in Navarra (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.21.2100438 · Cited by 86
“…three vaccines to control the spread of SARS-CoV-2, i.e. Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer, Mainz, Germany/New York, United States (US)), Moderna COVID-19 Vaccine (mRNA-1273, Moderna, Cambridge, US) and Vaxzevria (ChAdOx1 nCoV-19, Oxford-AstraZeneca, Cambridge, United Kingdom) [6-8].”
Richard, S. A., Pollett, S. D., Fries, A. C., Berjohn, C. M., Maves, R. C., Lalani, T., Smith, A. G., Mody, R. M., Ganesan, A., Colombo, R. E., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.51360 · Cited by 90
Bowman, C., Bouressam, M., Campion, S. N., Cappon, G. D., Catlin, N. R., Cutler, M. W., Diekmann, J., Rohde, C. M., Sellers, R. S., & Lindemann, C. (2021) · Reproductive Toxicology · doi:10.1016/j.reprotox.2021.05.007 · Cited by 88
Kumar, R., Yeni, C. M., Utami, N. A., Masand, R., Asrani, R. K., Patel, S. K., Kumar, A., Yatoo, M. I., Tiwari, R., Natesan, S. K. A., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.04.005 · Cited by 92
Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
Pine, M., Arora, G., Hart, T. M., Bettini, E., Gaudette, B. T., Muramatsu, H., Tombácz, I., Kambayashi, T., Tam, Y. K., Brisson, D., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.022 · Cited by 88
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
(2022) · doi:10.1038/s41467-022-32363-4 · Cited by 84
Lichen planus arising after COVID‐19 vaccination
Hiltun, I., Aldecoa‐Otalora, J. S., Martínez‐de‐Espronceda, I., Garcés, A., Llanos, C., Vives, R., & Yanguas, J. I. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17221 · Cited by 82
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Muhajarine, N., Adeyinka, D. A., McCutcheon, J., Green, K. L., Fahlman, M., & Kallio, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259513 · Cited by 93
“Evidence supporting COVID-19 vaccine safety and cost-effectiveness is mounting [9, 10], yet vaccine hesitancy and refusal continue to pose significant roadblocks to attaining herdimmunity level coverage.”
BackgroundKhan, T., Islam, M. J., Parihar, A., Islam, R., Jerin, T. J., Dhote, R., Ali, M., Laura, F. K., & Halim, M. A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100578 · Cited by 88
“Currently, there are no effective drugs or vaccines established for the treatment of COVID-19, although vaccine development is a time-consuming process that involves experimental to clinical trial settings, and no vaccine candidate has completed clinical trials yet [7,66 – 70].”
BackgroundFigueroa, J. M., Lombardo, M., Dogliotti, A., Flynn, L. P., Giugliano, R. P., Simonelli, G., Valentini, R. N., Ramos, A., Romano, P., Marcote, M., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s328486 · Cited by 84
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06235-0 · Cited by 98
Padoan, A., Dall’Olmo, L., Rocca, F. D., Barbaro, F., Cosma, C., Basso, D., Cattelan, A. M., Cianci, V., & Plebani, M. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.04.006 · Cited by 82
Zabaleta, N., Dai, W., Bhatt, U., Hérate, C., Maisonnasse, P., Chichester, J. A., Sanmiguel, J. C., Estelien, R., Michalson, K. T., Diop, C., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.08.002 · Cited by 91
“To date,severalofthesehavebeenapprovedonthebasisofahighly favorable safety and efficacy profile (Baden et al., 2021; Dagan et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021).”
InfluentialOtologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience
Wichova, H., Miller, M. E., & Derebery, M. J. (2021) · Otology & Neurotology · doi:10.1097/mao.0000000000003275 · Cited by 88
“highlight the common link between migraines and hearing loss, noting increased headache symptoms in the Pfizer vaccine trials (51% after second dose in older patients) compared with placebo (14% after second dose in older patients) (1,22).”
BackgroundJin, P., Li, J., Pan, H., Wu, Y., & Zhu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00481-y · Cited by 83
COVID-19 Vaccine Donations—Vaccine Empathy or Vaccine Diplomacy? A Narrative Literature Review
Su, Z., McDonnell, D., Li, X. A., Bennett, B., Šegalo, S., Abbas, J., Cheshmehzangi, A., & Xiang, Y. (2021) · Vaccines · doi:10.3390/vaccines9091024 · Cited by 81
“This is particularly true in light of the ever-evolving COVID-19 mutations, such as the Delta variant [3], which are situations that further highlight why vaccinations remain the most straightforward path into a post-pandemic reality [4].”
BackgroundSex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Bignucolo, A., Scarabel, L., Mezzalira, S., Polesel, J., Cecchin, E., & Toffoli, G. (2021) · Vaccines · doi:10.3390/vaccines9080825 · Cited by 93
“Efficacy data were available for the mRNA vaccines, BNT162b2BioNTech/Pfizer [10] and mRNA-1273-Moderna [11], and the non-replicative vector-based vaccines, Ad26.”
BackgroundInfluentialCook, C., Patel, N. J., D’Silva, K. M., Hsu, T. Y. T., DiIorio, M. A., Prisco, L. C., Martin, L. W., Vanni, K. M. M., Zaccardelli, A., Todd, D. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221326 · Cited by 78
“1Ann Rheum Dis Month 2021 Vol 0 No 0 Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases SARS- CoV-2 vaccines reduce the risk of COVID-19.”
BackgroundInfluentialTang, L., Hijano, D. R., Gaur, A. H., Geiger, T. L., Neufeld, E. J., Hoffman, J. M., & Hayden, R. T. (2021) · JAMA · doi:10.1001/jama.2021.6564 · Cited by 81
Collier, A.-R. Y., Brown, C., McMahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D. B., Ansel, J. L., Rowe, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6150 · Cited by 91
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
Kalnin, K. V., Plitnik, T., Kishko, M., Zhang, J., Zhang, D., Beauvais, A., Anosova, N. G., Tibbitts, T., DiNapoli, J., Ulinski, G., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00324-5 · Cited by 82
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
Ruddy, J. A., Boyarsky, B. J., Bailey, J. R., Karaba, A. H., Garonzik‐Wang, J., Segev, D. L., Durand, C. M., & Werbel, W. A. (2021) · AIDS · doi:10.1097/qad.0000000000003017 · Cited by 88
Ashhurst, A. S., Tang, A. H., Fajtová, P., Yoon, M. C., Aggarwal, A., Bedding, M. J., Stoye, A., Beretta, L., Pwee, D., Drelich, A. K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01494 · Cited by 97
Aliakbarinodehi, N., Gallud, A., Mapar, M., Wesén, E. V., Heydari, S., Jing, Y., Emilsson, G., Liu, K., Sabirsh, A., Zhdanov, V. P., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04829 · Cited by 98
Wang, W. B., Liang, Y., Jin, Y. Q., Zhang, J., Su, J. G., & Li, Q. M. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.108035 · Cited by 90
Lim, S. H., Stuart, B. L., Joseph‐Pietras, D., Johnson, M., Campbell, N. A., Kelly, A., Jeffrey, D. L., Turaj, A. H., Rolfvondenbaumen, K., Galloway, C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00364-3 · Cited by 87
“of cases) Na DLBCL (124) FL (93) EaTL (2) Transformed FL/MZL (6) CLL (51) aITL (7) PBML (3) MCL (21) BIa-aLCL (1) PCNSL (6) LPL (17) aLCL (3) Burkitt lymphoma (4) MZL (21) Subcutaneous panniculitis T-cell lymphoma (1) High grade B-cell lymphoma (1) Hairy cell leukemia (2) Richter’s transformation (2) NLPHL (6) T-cell…”
Characterization and Sequence Mapping of Large RNA and mRNA Therapeutics Using Mass Spectrometry
Vanhinsbergh, C. J., Criscuolo, A., Sutton, J. N., Murphy, K., Williamson, A. J. K., Cook, K., & Dickman, M. J. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00765 · Cited by 88
Chen, C., Boorla, V. S., Banerjee, D., Chowdhury, R., Cavener, V. S., Nissly, R. H., Gontu, A., Boyle, N. R., Vandegrift, K. J., Nair, M. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106480118 · Cited by 83
John, B. V., Deng, Y., Scheinberg, A. R., Mahmud, N., Taddei, T. H., Kaplan, D. E., Labrada, M., Baracco, G. J., & Dahman, B. A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.4325 · Cited by 82
Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply
Tuite, A. R., Zhu, L., Fisman, D. N., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-8137 · Cited by 81
Schramm, R., Costard‐Jäckle, A., Rivinius, R., Fischer, B., Muller, B. Z., Boeken, U., Haneya, A., Provazník, Z., Knabbe, C., & Gummert, J. F. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01880-5 · Cited by 85
Falco, A., Girardi, D., Corso, L. D., Yıldırım, M., & Converso, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257197 · Cited by 101
“Since then, COVID-19 has afflicted tens of millions of people in a worldwide pandemic [5], with major health (both physical and mental), social, and economic consequences [6–9].”
BackgroundCOVID-19 Vaccines: An Overview of Different Platforms
Kudlay, D. A., & Svistunov, A. А. (2022) · Bioengineering · doi:10.3390/bioengineering9020072 · Cited by 88
“BNT162b2 [55,56] mRNA 2 doses, 3-week interval 95.”
Espi, M., Charmetant, X., Barba, T., Mathieu, C., Pelletier, C. C., Koppe, L., Chalençon, E., Kalbacher, E., Mathias, V., Ovize, A., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.10.040 · Cited by 90
Amanzio, M., Mitsikostas, D. D., Giovannelli, F., Bartoli, M., Cipriani, G. E., & Brown, W. A. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100253 · Cited by 81
Development and deployment of COVID-19 vaccines for those most vulnerable
Koff, W. C., Schenkelberg, T., Williams, T. M., Baric, R. S., McDermott, A. B., Cameron, C., Cameron, M. J., Frieman, M. B., Neumann, G., Kawaoka, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1525 · Cited by 83
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.